How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma

SIMPLE SUMMARY: Lenalidomide is considered a key drug in the treatment of patients with multiple myeloma (MM), an incurable haematological cancer. In fact, most of the regimens used to treat early stage MM patients contain lenalidomide. This extensive use, however, has now led to treatment resistanc...

Descripción completa

Detalles Bibliográficos
Autores principales: de Arriba de la Fuente, Felipe, Montes Gaisán, Carmen, de la Rubia Comos, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818178/
https://www.ncbi.nlm.nih.gov/pubmed/36612152
http://dx.doi.org/10.3390/cancers15010155

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818178/
https://www.ncbi.nlm.nih.gov/pubmed/36612152
http://dx.doi.org/10.3390/cancers15010155

Ejemplares similares